PL3377089T3 - Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego - Google Patents

Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego

Info

Publication number
PL3377089T3
PL3377089T3 PL16809895T PL16809895T PL3377089T3 PL 3377089 T3 PL3377089 T3 PL 3377089T3 PL 16809895 T PL16809895 T PL 16809895T PL 16809895 T PL16809895 T PL 16809895T PL 3377089 T3 PL3377089 T3 PL 3377089T3
Authority
PL
Poland
Prior art keywords
cdnf
compositions
nervous system
central nervous
system diseases
Prior art date
Application number
PL16809895T
Other languages
English (en)
Inventor
Henri Huttunen
Mikko Airavaara
Mart Saarma
Original Assignee
Herantis Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Herantis Pharma Plc filed Critical Herantis Pharma Plc
Publication of PL3377089T3 publication Critical patent/PL3377089T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PL16809895T 2015-11-18 2016-11-18 Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego PL3377089T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20155857 2015-11-18
PCT/FI2016/050813 WO2017085362A1 (en) 2015-11-18 2016-11-18 Compositions comprising cdnf or manf for use in the intranasal treatment of central nervous system diseases
EP16809895.2A EP3377089B1 (en) 2015-11-18 2016-11-18 Compositions comprising cdnf for use in the intranasal treatment of central nervous system diseases

Publications (1)

Publication Number Publication Date
PL3377089T3 true PL3377089T3 (pl) 2020-06-29

Family

ID=57543060

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16809895T PL3377089T3 (pl) 2015-11-18 2016-11-18 Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego

Country Status (6)

Country Link
US (1) US20190192629A1 (pl)
EP (1) EP3377089B1 (pl)
JP (1) JP7201432B2 (pl)
ES (1) ES2789723T3 (pl)
PL (1) PL3377089T3 (pl)
WO (1) WO2017085362A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110499330A (zh) * 2018-05-16 2019-11-26 上海市同济医院 重组腺相关病毒载体及其应用
EP3838912A1 (en) * 2019-12-20 2021-06-23 Herantis Pharma Oyj Retro-inverso peptides
WO2021160938A1 (en) 2020-02-13 2021-08-19 Herantis Pharma Oyj Systemic administration of a pharmaceutical composition comprising cdnf or manf polypeptide for use in the treatment of reperfusion injury

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
WO2000033813A1 (en) * 1998-12-09 2000-06-15 Chiron Corporation Administration of neurotrophic agents to the central nervous system
EP1285000B1 (en) * 2000-05-31 2004-11-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Adnf mixtures for enhancing learning and memory
EP1373502B8 (en) * 2001-03-20 2010-12-22 Amarantus Therapeutics, Inc. Dopaminergic neuronal survival-promoting factors and uses thereof
AU2006217027A1 (en) * 2005-02-23 2006-08-31 Alza Corporation Intranasal administration of active agents to the central nervous system
DK1969003T3 (da) 2005-12-14 2010-12-13 Hermo Pharma Ltd Anvendelser af et neurotrofisk faktor-protein
EP2087008A1 (en) 2006-10-19 2009-08-12 The Regents of the University of California TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN alphaVbeta6
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
EP4088769A1 (en) 2011-03-03 2022-11-16 Impel Pharmaceuticals Inc. Nasal drug delivery device
FI20115870A0 (fi) 2011-09-05 2011-09-05 Urmas Arumaee Neuroprotektiiviset soluihin tunkeutuvat peptidit
WO2014066686A1 (en) 2012-10-24 2014-05-01 Amarantus Bioscience Holdings, Inc. Brain targets for neurotrophic factors to treat neurodegenerative disease

Also Published As

Publication number Publication date
EP3377089A1 (en) 2018-09-26
WO2017085362A1 (en) 2017-05-26
JP7201432B2 (ja) 2023-01-10
EP3377089B1 (en) 2020-04-08
US20190192629A1 (en) 2019-06-27
ES2789723T3 (es) 2020-10-26
JP2018538275A (ja) 2018-12-27

Similar Documents

Publication Publication Date Title
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
ZA201901279B (en) Compositions and methods for treatment of neurological disorders
IL248732A0 (en) Compounds for the treatment of ophthalmological diseases and disorders
PL3349783T3 (pl) Kompozycje i sposoby do leczenia chorób
SG11201705093UA (en) Composition for treating il-6-related diseases
IL246791A0 (en) Compositions and methods for treating eye diseases
IL259861A (en) Methods and preparations for the treatment of disorders related to seizures
IL256684B (en) Medicinal compounds and preparations for the treatment of social disorders and substance use disorders
SG11201609254YA (en) Therapeutic placental compositions, methods of making and methods of use
SG11201701377YA (en) Compositions and methods to treat vision disorders
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
SG11201704829QA (en) Methods and compositions for treating brain diseases
PT3160464T (pt) 6-hidroxibuspirona para uso no tratamento de transtornos do movimento
GB201412578D0 (en) Treatment of neurological diseases
GB201408387D0 (en) Treatment of respiratory disorders
GB201612043D0 (en) Composition for treatment of disorders
IL253847A0 (en) Methods of treating diseases
GB201607388D0 (en) Treatment of impulsivity-related disorders
IL251736B (en) Methods and compositions for the treatment of radiation-related disorders
PL3377089T3 (pl) Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego
IL252707B (en) Compositions and methods for treating diseases
EP3200795A4 (en) Use of agents for treating fat-related disorders
HUE066000T2 (hu) (+)-Azaszetron fül rendellenességek kezelésében történõ alkalmazásra
IL254140A0 (en) Preparations and combinations for use in the treatment of angiogenic diseases and disorders